home / stock / nbtx / nbtx quote
Last: | $5.455 |
---|---|
Change Percent: | 4.1% |
Open: | $5.31 |
Close: | $5.24 |
High: | $5.555 |
Low: | $5.31 |
Volume: | 2,821 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.455 | $5.31 | $5.24 | $5.555 | $5.31 | 2,821 | 07-03-2024 |
$5.24 | $5.24 | $5.24 | $5.24 | $5.24 | 719 | 07-02-2024 |
$5.35 | $5.22 | $5.35 | $5.38 | $5.0532 | 5,598 | 07-01-2024 |
$5 | $5.51 | $5 | $5.51 | $4.91 | 10,562 | 06-28-2024 |
$5.6 | $5.4 | $5.6 | $5.6787 | $5.4 | 7,670 | 06-27-2024 |
$5.4 | $5.31 | $5.4 | $5.48 | $5.19 | 16,839 | 06-26-2024 |
$4.88 | $4.4 | $4.88 | $5 | $4.4 | 33,756 | 06-25-2024 |
$4.36 | $4.29 | $4.36 | $4.36 | $4.14 | 10,792 | 06-24-2024 |
$4.16 | $4.3 | $4.16 | $4.47 | $4.16 | 19,591 | 06-21-2024 |
$4.2066 | $4.46 | $4.2066 | $4.53 | $4.2066 | 7,893 | 06-20-2024 |
$4.54 | $4.52 | $4.54 | $4.709 | $4.41 | 9,539 | 06-19-2024 |
$4.54 | $4.52 | $4.54 | $4.709 | $4.41 | 9,539 | 06-18-2024 |
$4.83 | $4.64 | $4.83 | $4.86 | $4.6301 | 11,549 | 06-17-2024 |
$4.6 | $5 | $4.6 | $5 | $4.6 | 20,242 | 06-14-2024 |
$5.35 | $5.32 | $5.35 | $5.41 | $5.32 | 2,971 | 06-13-2024 |
$5.32 | $5.6 | $5.32 | $5.6 | $5.32 | 4,285 | 06-12-2024 |
$5.79 | $5.62 | $5.79 | $5.79 | $5.62 | 1,834 | 06-11-2024 |
$5.6242 | $5.5901 | $5.6242 | $5.6242 | $5.5901 | 1,592 | 06-10-2024 |
$5.7 | $5.92 | $5.7 | $6.0096 | $5.565 | 7,599 | 06-07-2024 |
$6.32 | $6.48 | $6.32 | $6.48 | $6.31 | 2,245 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...